DigestRedComo funciona
Red
/
Empresas
Ge
No verificado

Genentech

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

76 Comunicados de prensa

Ver todos los comunicados de prensa
09/03/2026
Industria
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Farmacéutica
Ir de compras
Salud
Oncología
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
Fuente
Genentech
Editor
Business Wire
1.00
0
06/03/2026
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
Fuente
Genentech
Editor
Business Wire
1.00
0
05/03/2026
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
Fuente
Genentech
Editor
Business Wire
1.00
0
02/03/2026
Industria
Salud
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
Fuente
Genentech
Editor
Business Wire
1.00
0
20/02/2026
Industria
Oncología
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
Fuente
Genentech
Editor
Business Wire
1.00
0
20/02/2026
Industria
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Sanidad
Farmacéutica
Salud
Oncología
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
Fuente
Genentech
Editor
Business Wire
1.00
0
16/02/2026
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease
Fuente
Genentech
Editor
Business Wire
1.00
0
07/02/2026
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Sanidad
Farmacéutica
Salud
Industria
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
Fuente
Genentech
Editor
Business Wire
1.00
0
27/01/2026
Ciencia
Cardiología
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Industria
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
Fuente
Genentech
Editor
Business Wire
1.00
0
20/01/2026
Biotecnología
Industria
Salud
Farmacéutica
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility
Fuente
Genentech
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0